


CLAIMS

What is claimed is:

1. A compound of Formula (I):



wherein:

X is NH or O;

R₁ is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

R₂ is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl; or R₂ is absent;

--- is a single bond when R₂ is present, or --- is a double bond when R₂ is absent; and

Ring A is a 5, 6 or 7-membered carbocyclic ring or a 5, 6 or 7-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, hydroxy, thioxy, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

2. The compound according to claim 1 wherein:

X is NH;

R₁ is H or hydroxy;


R₂ is H or absent;

--- is a single bond when R_2 is H, or --- is a double bond when R_2 is absent;

and

Ring A is a 5-membered carbocyclic ring or a 5-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

3. The compound according to claim 1 having Formula (If):




wherein:

R_1 is H or hydroxy; and

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.


4. The compound according to claim 1 having Formula (Ih):



wherein:

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy and C_{3-5} cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.


5. The compound according to claim 1 having Formula (Ih):



wherein:

Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof..

6. The compound according to claim 1 having Formula (Ih):



wherein:

- Ring A is substituted with 1 or 2 substituents selected from the group consisting of halogen, *n*-propyl, *n*-butyl, C₁₋₄ alkoxy and C₃₋₅ cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.
7. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
8. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
9. The compound according to claim 1 that is 6-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
10. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
11. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
12. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
13. The compound according to claim 1 that is 5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

14. The compound according to claim 1 that is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
15. The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
16. The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
17. The compound according to claim 1 that is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
18. The compound according to claim 1 that is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
19. The compound according to claim 1 that is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
20. The compound according to claim 1 that is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
21. The compound according to claim 1 that is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
22. The compound according to claim 1 that is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
23. The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazol-6-ol or a pharmaceutically acceptable salt, solvate or hydrate thereof.

24. The compound according to claim 1 that is 5-Methoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
25. The compound according to claim 1 that is 5,5-Difluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
26. The compound according to claim 1 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
27. A pharmaceutical composition comprising a compound according to any one of claims 1 to 26 in combination with a pharmaceutically acceptable carrier.
28. A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 26.
29. The method according to claim 27 wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
30. The method according to claim 27 wherein said metabolic-related disorder is atherosclerosis.
31. A method of raising HDL in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to any one of claims 1 to 26.
32. A compound according to any one of claims 1 to 26 for use in a method of treatment of the human or animal body by therapy.
33. A compound according to any one of claims 1 to 26 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy.
34. A compound according to any one of claims 1 to 26 for use in a method of treatment of a metabolic-related disorder of the human or animal body by therapy wherein said

metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

35. A compound according to any one of claims 1 to 26 for use in a method of treatment of atherosclerosis of the human or animal body by therapy.
36. A compound according to any one of claims 1 to 26 for use in a method of raising HDL of the human or animal body by therapy.
37. Use of a compound according to any one of claims 1 to 26 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder.
38. Use of a compound according to any one of claims 1 to 26 for the manufacture of a medicament for use in the treatment of a metabolic-related disorder selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
39. Use of a compound according to any one of claims 1 to 26 for the manufacture of a medicament for use in the treatment of atherosclerosis.
40. Use of a compound according to any one of claims 1 to 26 for the manufacture of a medicament for use in raising HDL in an individual.
41. A method of producing a pharmaceutical composition comprising admixing a compound according to any one of claims 1 to 26 and a pharmaceutically acceptable carrier.